Antibody-Targeted Precision Medicines: Strategies for Overcoming Development Challenges

Antibody-Targeted Precision Medicines: Strategies for Overcoming Development Challenges

Brought to you by WuXi AppTec

Overview

Antibody-targeted therapies—including ADCs, AOCs, and DACs—are reshaping precision medicine by enabling highly selective delivery of potent therapeutic agents. These modalities offer new opportunities in oncology and beyond but present complex challenges in design, conjugation, and optimization. This white paper examines the structural principles and technical hurdles that influence the success of antibody-targeted drugs. It also outlines strategies to mitigate risks and accelerate development.

Key Objectives:

Explaining differences between ADC, AOC, and DAC modalities and their therapeutic applications.
Identify key challenges in antibody engineering, payload design, and linker selection.
Highlight how CRDMO partnerships streamline development and reduce risk.

Brought to you by:

Please complete the form to download the white paper.

Forwarded this link? Clear the form

Email Address*

Salutation*

First Name*

Last Name*

Company*

Job Title

Address 1*

City*

State*

Zip / Post Code*

Country/Territory/Area*

Business Phone*

I would like to receive C&EN’s weekly newsletter with the latest in chemistry news

I would like to receive more information on products and services from the American Chemical Society

address2

*By submitting this form, you agree to receive more information on related products and services from the American Chemical Society and its sponsor via email. You understand that you can withdraw your consent at any time. ACS takes your privacy seriously. For more information, please see the ACS Privacy Policy.